Ironwood Pharmaceuticals, Inc.
Stable Solid Formulation of GC-C Receptor Agonist Polypeptide Suitable for Oral Administration

Last updated:

Abstract:

Solid, stable formulations of linaclotide suitable for oral administration are described herein as are methods for preparing such formulations. The formulations described herein contain a polypeptide consisting of the amino acid sequence Cys Cys Glu Tyr Cys Cys Asn Pro Ala Cys Thr Gly Cys Tyr ("linaclotide"; SEQ ID NO:1) or a pharmaceutically acceptable salt thereof. The linaclotide formulations described herein are stable and have a sufficient shelf life for manufacturing, storing and distributing the drug.

Status:
Application
Type:

Utility

Filling date:

7 Jan 2022

Issue date:

28 Apr 2022